Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

10-day more efficient than 14-day nonbismuth quadruple therapy for H. pylori eradication

24 Jun 2020

The 10-day concomitant nonbismuth quadruple regimen for the treatment of Helicobacter pylori infection remains the most efficient strategy as compared with the 14-day therapy, results of a Greek study have shown.

A total of 364 patients with newly diagnosed H. pylori infection were randomly assigned to receive either a 10-day or a 14-day concomitant nonbismuth quadruple therapy. The investigators assessed the treatment outcome using C13-urea breath test and/or histology at least 4 weeks after therapy. They also performed intention-to-treat and per-protocol analyses of the eradication rates. Secondary outcomes were patient adherence, safety, and the impact of prior antibiotic exposure in treatment efficacy.

The intention-to-treat analysis revealed comparable overall eradication rates for the 10- and 14-day treatments (87.9 percent vs 87.4 percent; p=1.000). In the per-protocol analysis, the corresponding rates were 93 percent and 94.1 percent (p=0.859). Compliance rates were excellent in both treatment arms (99.5 percent for the 10-day vs 96.2 percent for the 14-day strategy; p=0.067).

Few serious adverse events that led to the discontinuation of both regimens were reported, with no statistical difference between the two groups (0.5 percent in the 10-day vs 2.2 percent in the 14-day group; p>0.05). In terms of treatment efficacy, previous antibiotic exposure was not significant.

“In Greece, a region with >20-percent clarithromycin resistance where bismuth is unavailable, the 10-day quadruple concomitant scheme has already been adopted as the accepted first-line H. pylori eradication treatment,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.